EQS-News: Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
Retrieved on:
Sunday, December 18, 2022
European Medicines Agency, Immunotherapy, CD95L, PRIME, Mortality, CD95, SOC, MDS, Safety, Federation, Cancer, Priority, TNF, GITR, Degenerative disease, Doctor of Philosophy, Immunoglobulin G, TRAIL, Lymphocytopenia, III, AbbVie, Immune system, CD40, COVID-19, Disease, FC, HIV disease progression rates, Standard of care, Microdeletion syndrome, Oxygen, Death, WHO, Ventilation, Glioblastoma, Patient, Pharmaceutical industry, Asunercept, EU
The multicenter, double-blind, placebo-controlled trial aims to enroll more than 600 hospitalized patients requiring oxygen in nine different countries.
Key Points:
- The multicenter, double-blind, placebo-controlled trial aims to enroll more than 600 hospitalized patients requiring oxygen in nine different countries.
- Following the successful controlled ASUNCTIS phase II study, the ASUCOV trial aims to confirm the clinical results in a larger study population.
- The secondary endpoints of the ASUCOV trial assess the reduction of progression to more severe disease, all-cause mortality, and progression to invasive ventilation.
- We hope to provide an effective treatment option for hospitalized COVID-19 patients because we still see too many deaths worldwide.